A Randomized, Prospective Trial of 2-6 Weeks Pre-Operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - Response in Molecular Profile (AFTER-Study)
Phase of Trial: Phase II
Latest Information Update: 25 May 2016
At a glance
- Drugs Anastrozole (Primary) ; Fulvestrant (Primary) ; Tamoxifen
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms AFTER
- 10 May 2016 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.
- 10 May 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2018.
- 12 Dec 2015 Interim results (n=28) presented at the 38th Annual San Antonio Breast Cancer Symposium.